News

Piramal Pharma exercises call option to acquire balance 26% stake in Yapan Bio

18-Nov-2026 | 17:35

 Piramal Pharma, acting under the authority delegated by the Board, has approved the exercise of the Company's call option to acquire the balance 26% equity stake in Yapan Bio (Yapan), a subsidiary of the Company, from its existing shareholders (the Proposed Transaction).

Consequent to the exercise of the call option, the Company is engaged in discussions with the shareholders of Yapan in relation to matters necessary for consummation of the Proposed Transaction. The final terms of the acquisition, including the acquisition consideration and the effective date of transfer of shares, are yet to be finalized.

Yapan is a Contract Development and Manufacturing Organization that specializes in process development, characterization and Phase I/II GMP manufacturing services for vaccines and biologics.

Upon completion of the proposed transaction the Company's shareholding in Yapan is expected to increase from the existing 74% to 100%, and Yapan will become a wholly owned subsidiary of the Company.